studies on clinically important nitrogen and sulphur...
Post on 19-Oct-2020
2 Views
Preview:
TRANSCRIPT
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 60
Part 2
In part-II, we have installed three medicinally important heterocycles i.e.
pyrazole, 1,3,4-oxadiazole and pyridine. It is our ongoing process to search for
novel bio-active molecules.
Introductory features of pyrazoles
Pyrazoles belong to the family of azoles, i.e. five-member ring containing only
nitrogen and carbon atoms, ranging from pyrrole to pentazole. According to
Albert’s classification, they are �-excessive, N-heteroaromatic derivatives and
according to Kauffmann’s arenology principle, as a substituted carbon, they are
analogues of amines and as substituted nitrogen they are analogues of halogens,
i.e. pseudohalogens. Synthesis of pyrazole and its N-aryl analogues has been
subject of consistent interest because of the wide applications of such
heterocycles in pharmaceutical as well as in agrochemical industry.1,2 Numerous
compounds containing pyrazole moiety have been shown to exhibit anti-
inflammatory,3 analgesic,4 antihyperglycemic,5 antibacterial,6 anticancer7 and
anti-HIV8 activity, as well as useful activities in conditions like schizophrenia9
and hypertension.10
1-Phenylpyrazole moiety is present in several drug candidates for treatment of
various diseases such as cyclooxygenase-2 (Cox-2) selective inhibitors, IL-1
synthesis inhibitors and protein kinase inhibitors etc.11-14 Similarly, few of 1,5-
diarylpyrazole derivatives exhibit non-nucleoside HIV-1 reverse transcriptase
inhibitor activity15 along with Cox-2 inhibitor.13,14 The corresponding 1,3,5-
triaryl-4-alkylpyrazoles have been recently identified as efficient ligands for
estrogen receptor displaying high binding affinities and selective transcriptional
efficacy for ERI subtype.16-19
In the last 20 years pyrazole ring has attracted much attention as it has become
fairly accessible and shows diverse properties. Besides traditional interest in
pyrazole derivatives, pyrazoles containing sulfonic group at N position have
exhibited promising antimicrobial activity.20 They are also studied as
antioxidants, as interesting complexing agents for analysis and separation of
cations. They are also reported for significant bacteriostatic, bactericidal and
fungicidal action.21
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 61
Commercially available pyrazole based analogues
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 62
Synthetic study of pyrazoles
Most of the methods for the synthesis of pyrazoles involve approaches based on
either
(i) Cyclocondensation of 1,3-dicarbonyl compounds and their equivalent 1,3-
dienophilic synthons such as propargylic ketones,
dialkylamino/alkoxy/chloro ketones with arylhydrazines.
(ii) Intermolecular [2+3] cycloadditions of 1,3-dipoles to alkynes22-30.
However, the appealing generality of these methods is somewhat vitiated due to
the frequent formation of regioisomeric mixtures of unsymmetrical pyrazoles in
these reactions. Therefore, several elegant methods for the synthesis of
unsymmetrical substituted pyrazoles are reported in literature. Before presenting
the results of our work, a brief literature survey on some of the recent synthesis
of pyrazoles and their derivatives have been discussed. Among these methods,
few selected recent examples have been highlighted in the following.
Mikulskiene G et al31 have synthesized some new 1-aryl-4-[(3,5–dimethylpyrazole-
1-yl)carbonyl]-2-pyrrolidinones (3a,b) by condensation of hydrazides (2a,b) with
2,4-pentanedione in 2-propanol in presence of a catalytic amount of hydrochloric
acid.
Giacomelli G et al32 have developed synthesis of 1,4,5-trisubstituted pyrazoles (8) from meldrum acid (4) under microwave conditions. The meldrum’s acid (4) was
acylated with acid chlorides and the resulting products (5) were reacted with
amines affording the substituted β-ketoamides (6) in good yields. Subsequent
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 63
reaction of β-ketocarbonyl compounds (7) with N,N-dimethylformamide
dimethylacetal (DMF-DMA) followed by cyclization with substituted
monohydrazines furnished the corresponding 1,4,5-trisubstituted pyrazoles (8) in
good yields.
Recently Lee K Y et al33 have reported the synthesis of 1,3,4,5-tetrasubstituted
pyrazoles (10) involving the reaction of Baylis-Hillman adducts (9) and hydrazine
hydrochloride in dichloroethane at 50-70 °C.
Alinezhad H et al34 have reported an efficient protocol for the one pot
regioselective synthesis of 4-bromopyrazole derivatives (13) and (14) from 1,3-
diketones (11), arylhydrazines (12) and N-bromosaccharin, in the presence of
silica gel supported sulfuric acid as heterogeneous catalyst, under solvent free
conditions.
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 64
Sharma P K et al35 synthesized a novel series of pyrazolylpyrazolines (17) by the
reaction of appropriate chalcones (16) derived from different pyrazole aldehydes
(15) and acetophenone derivatives with 4-hydrazinobenzene- sulfonamide
hydrochloride in ethanol. All the newly synthesized target compounds (5a–k)
were screened for their anti-inflammatory activity using carrageenan-induced rat
paw edema assay. Additionally, the synthesized compounds were evaluated for
their in vitro antimicrobial activity against two Gram-positive bacteria and two
Gram-negative bacteria.
Mohamed S et al36 have reported a novel one-pot synthesis of pyrazoles. In this
method four component coupling of a terminal alkyne (18), hydrazine, carbon
monoxide and an aryl iodide (19) furnishes pyrazole derivatives (20) in presence
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 65
of palladium catalyst. The reaction proceeds at room temperature and an
ambient pressure of carbon monoxide in an aqueous solvent system.
Pharmalogical profile of pyrazoles
Fadda A A et al37 have synthesized (3-methyl-5-(phenylamino)-1H-pyrazol-4-
yl)(phenyl)methanone (21). These compounds showed significant molluscicidal
activity to Biomphalaria alexandrina snails. Ming L et al38 have reported the
formation of ethyl 5-amino-1-(5’-methyl-1’-t-butyl-4’-pyrazolyl)carbonyl-3-
methylthio-1H-pyrazole-4-carboxylate (22) by treatment of ethyl 2-cyano-3,3-
dimethylthioacrylate with 1-t-butyl-5-methyl-4-hydrazinocarbonylpyrazole. These
compounds showed fungicidal and plant growth regulation activities. Farag A M
et al39 have reported the formation of 3-(3-acetyl-1-phenyl-1H-pyrazole-4-
carbonyl)-1,5-diphenyl-1H-pyrazole-4-carbonitrile (23) and compounds showed a
significant cytotoxic activity in a nano molar range against certain types of
breast and ovarian tumors with tolerable toxicity.
Chovatia P T et al40 have synthesized 1-acetyl-3-aryl-5-{1-phenyl-3-[p-
(methylthio)phenyl]-pyrazol-4-yl}-4,5-dihydro-(1H)-pyrazoles (24) by the reaction
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 66
of 1-aryl-3-{1-phenyl-3-[p-(methylthio)phenyl]pyrazol-4-yl}-2-propen-1-ones with
hydrazine hydrate in glacial acetic acid. These synthesized compounds were
tested in vitro for their antitubercular, antibacterial and antifungal activities.
Badawey EI-S A et al41 have reported novel 1-[6-amino-5-cyano-4-(aryl)pyrimidin-
2-yl]-4-(2-hydroxyethyl)-3-methylpyrazoline-5-ones (25) and 2-[6-amino-5-cyano-
4-(aryl)pyrimidin-2-yl]-1,2,4,5,6,7-hexahydro-3H-indazol-3-ones (26). These
compounds were shown to possess anti-inflammatory, analgesic and antipyretic
activities.
Banoglu E et al42 have synthesized some new amide derivatives of 3-[1-(3-
pyridazinyl)-5-phenyl-1H-pyrazole-3-yl]propanoic acid (27). These compounds
exhibited potent analgesic activity. Karthikeyan M S et al43 have reported the
synthesis of 1-aryloxy-3-aryl-5-hydroxy-5-arylpyrazolines (28) by the reaction of
chalcone dibromides with aryloxy acid hydrazides in the presence of triethyl-
amine and ethanol. These synthesized compounds showed very good
antibacterial and antifungal activities. Perali R S et al44 were synthesized a series
of 1,3-diarylpyrazole ligated DHPMs possessing lipophilic carbamoyl moiety (29) by utilizing Biginelli reaction and displayed good in vitro anticancer activity
against MCF-7 human breast cancer (HBC) cell line using sulforhodamine B
(SRB) assay and antitubercular activity against Mycobacterium tuberculosis
(MTB) H37Rv using Microplate Alamar Blue Assay (MABA).
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 67
Moreover, pyrazoles are reported to possess anticancer, germicidal, antidiretic,
antihistamine, antidiabitic, antirheumatic, antineoplastic, anti HIV and
antifertility activities. The pharmaceutical importance of these compounds lies in
the fact that they can be effectively utilized as antibacterial, antifungal, antiviral,
antiparasitic, and antitubercular agents. As evident from the literature, in recent
years significant research work in heterocyclic chemistry has been devoted to
pyrazole containing different aryl groups as substituents.
Introductory features of pyridines
Pyridine is a simple and important heterocyclic aromatic organic compound with
the formula C5H5N (30). This colourless liquid with a distinctive fish-like odour is
structurally related to benzene, wherein one CH group in the six-membered ring
is replaced by a nitrogen atom. Pyridines came to prominence in the 1930s with
the recognition of the importance of niacin (31) for the prevention of dermatitis
and dementia. In the 1940s a new major application was discovered for 2-
vinylpyridine (32) as a constituent in latex that promoted the binding of rubber to
tyre cord. Demand for 2-picoline (33) for latex production outstretched its
availability from coal tar sources and so industries developed an industrial
synthesis of 2-picolines and 4-picolines (34).
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 68
Since the middle of the last century, pyridine has assumed an important role in
our understanding of the chemistry of biological systems. It plays a key role
catalyzing both biological and chemical systems. In many enzymes of living
organisms, it is the prosthetic pyridine nucleotide (NADP) that is involved in
various oxidation–reduction processes.45 Other evidence of the potent activity of
pyridine in biological systems is its presence in the important vitamins niacin
and pyridoxine (vitamin B6) and also in highly toxic alkaloids such as nicotine.46
The pyridine ring is also ubiquitous in agrochemicals.47
In addition to these important biological applications, pyridine is also of great
utility in preparative organic chemistry (Scheme 6), for example, DMAP (35), which is used in demanding process-scale acylation reactions and in the
activation of carboxylic acids without racemization of a sensitive chiral
α-functionality. An axially chiral analogue of DMAP (36) is developed to carry out
enantioselective acylation, a reaction formerly dependent on the use of
enzymes.48 Within synthetic organic chemistry, pyridines are extensively utilized
in coordination chemistry: bipyridines such as (37) and terpyridines such as (38)
have an excellent ability to complex various metal ions, including ruthenium,
zinc and copper. These functional ligands have found a multitude of applications
in highly sensitive analytical reagents, sensor systems, enantioselective
synthesis, luminescent agents for labelled peptide synthesis and building blocks
for supramolecular chemistry.49
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 69
Commercially available pyridine based analogues
Synthetic study of pyridines
Joshi H S et al50 have synthesized some new cyanopyridines (40) from 1-[p-(3’-
chloro-2’-benzo(b)thiophenoylamino)-phenyl]-3-aryl-2-propen-1-ones (39) and
malononitrile in the presence of ammonium acetate and also reported their
antitubercular and antimicrobial properties. Xiong X et al51 have synthesized
some polysubstituted pyridines (43) by the one-pot reaction of 1,3-dicarbonyl
compound (41), alkynone (42) and ammonium acetate in alcoholic solvents. This
new three-component heteroannulation reaction proceeds under mild conditions
in the absence of an additional acid catalyst.
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 70
Andersson H et al52 have reported that addition of Grignard reagents to pyridine
N-oxides (44) in THF at room temperature and subsequent treatment with acetic
anhydride at 120°C yields 2-substituted pyridines (45) in good yields. Trost B M
et al53 have synthesized substituted pyridine (47) derivatives from unsaturated
ketones and aldehydes (46) with excellent regiocontrol.
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 71
Fathalla O E M et al54 have synthesized iminopyridines (49) and pyridones (50) from 3-(4-acetylphenyl)-2-[(E)-2-(2-furyl)vinyl]-(3H)-quinazolin-4-one (48) with
good yield and evaluated their antimicrobial and anti-inflammatory properties. They used Escherichia coli as Gram negative and Staphylococcus aureus as Gram
positive bacteria, Candida albicans as yeast and Aspergillus niger as fungi in
antimicrobial activity. Anti-inflammatory activity was checked with respect to
Indomethacin.
Thirumurugan P and Perumal P T55 have prepared 2-(1H-Indol-3-yl)-6-methoxy-
4-(aryl)pyridine-3,5-dicarbonitrile derivatives (53) through one-pot multi-
component reaction using indium chloride as catalyst under reflux condition.
Particularly valuable features of this method include high yields of products in
short reaction time and broad substrate scope. It is an efficient and promising
synthetic strategy to build indol-3-yl pyridines. Barluenga J et al56 have
synthesized trisubstituted pyridines are regioselectively through multicomponent
and one-pot processes promoted by a bifunctional Pd catalyst.
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 72
Palacios F et al57 have reported the reaction of N-vinylic phosphazenes (58a-c) with α,β-unsaturated ketones (59) leads to the formation of pyridines (61)
derived from β-amino acids in a regioselective fashion through the formation of
dihydropyridines (60) substituted with carboxylate or phosphonate groups.
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 73
Pharmalogical profile of pyridines
The pyridine substructure is one of the most important heterocycle found in
natural products, pharmaceuticals, and functional materials.58,59 Pyridines and
its analogues were reported to possess anticonvulsant,60,61 cardiotonic,62
antihypertensive,63 �-adrenergic blocking activity.64 Recent papers have reported
novel 1,4-dihydropyridine derivatives as calcium channel modulators,65 as Ca-
blockers against endothelial cell oxidative injury,66 with vasodilating activity67
and as nonpeptide HIV-1 protease inhibitors.68 Pyridine derivatives containing
multi-functional groups such as streptonigrin, streptonigrone and lavendamycin
are reported as anticancer drugs, and cerivastatin is reported as the HMGCoA
enzyme inhibitors.69 Moreover, substituted pyridines are reported as leukotriene
B-4 antagonists.70,71
Narendar P et al72 have synthesized a series of 2-substituted-pyridines. The
compounds were assayed against seizures induced by the maximal electro shock
(MES) and pentylenetetrazole (scMet). Neurologic deficit was evaluated by the
rotarod test. The decrease in the elevated motor activity by introceptive chemical
stimuli (amphetamine antagonistic activity) was studied at the dose level of 25
and 50 mg/kg, antihistaminic and cardiac activity were also studied. All the
compounds exhibited significant anticonvulsant activity.
Bach P et al73 have described the development of a new series of P2Y12 receptor
antagonists (64) endowed with a sulfonylurea group. The improved affinity
observed in the in vitro binding assay also translated to the potency observed in
the WPA aggregation assay and the observed in vitro ADME properties translates
to the in vivo PK properties observed in rat. In addition, we found that the
chemical stability of the sulfonylureas during prolonged storage in solution was
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 74
related to the sulfonyl urea linker and depended on the type of solvent and the
substitution pattern of the sulfonyl urea functionality. Hayashi S et al74 designed
a series of novel [2-{[(4-substituted or 4,5-disubstituted)-pyridin-2-yl]carbonyl}-(5-
or 6-substituted or 5,6-disubstituted)-1H-indol-3-yl]acetic acid (65) analogues
and evaluated to identify potent and selective COX-2 inhibitors as potential
agents against inflammatory diseases. As significant findings, the present study
clarified unique structure activity relationship of the analogues toward potent
and selective COX-2 inhibition in vitro, and identified 2-{6-fluoro-2-[4-methyl-2-
pridinyl)carbonyl]-1H-indol-3-yl}acetic acid as a potent and selective COX-2
inhibitor in vitro that demonstrated orally potent anti-inflammation efficacy
against carrageenan-induced oedema formation in the foot of SPF/VAF male SD
rats as a peripheral inflammation model in vivo.
Prasanthi G et al75 have developed dialkyl 4-(benzo[d][1,3]dioxol-6-yl)-1,4-
dihydro-2,6-dimethyl-1-substituted pyridine-3,5-dicarboxylate derivatives (66) as
isosteric analogues of isradipine and nifedipine, by the replacement of
benzofurazanyl and 2-nitrophenyl groups respectively with benzo[d][1,3]dioxo-6-
yl group, as potential anticonvulsants. All the compounds were tested for
anticonvulsant activity using maximal electroshock and subcutaneous
pentylenetetrazole induced seizure methods. Compound possessing free -NH
group in 1,4-dihydropyridine ring, diethyl ester functionality at the positions 3
and 5 showed significant anticonvulsant and antioxidant activities. This was also
supported by molecular properties prediction data. Selected compounds were
evaluated for antinociceptive activity in capsaicin induced nociception assay at
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 75
10 mg/kg body weight, but displayed no significant activity at the tested dose.
Khidre R E et al76 have synthesized a new series of 1-substituted amino-4,6-
dimethyl-2-oxo-pyridine-3-carbonitrile such as ethane-1,2-diaminopyridine (67) using 1-amino-4,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonitrile as a key
intermediate. The antibacterial and antifungal activities of the synthesized
compounds were evaluated. The obtained data indicated that the majority of the
tested compounds exhibited both antibacterial and antifungal activities.
Acharya B N et al77 have reported a series of 1,3,5-trisubstituted pyrazolines (68) and evaluated for in vitro antimalarial efficacy against chloroquine sensitive
(MRC-02) as well as chloroquine resistant (RKL9) strains of Plasmodium
falciparum. The activity was at nano molar concentration. β-hematin formation
inhibition activity (BHIA50) of the pyrazolines were determined and correlated with
antimalarial activity. A reasonably good correlation (r = 0.62) was observed
between antimalarial activity (IC50) and BHIA50. This suggests that antimalarial
mode of action of this class of compounds appears to be similar to that of
chloroquine and involves the inhibition of hemozoin formation. Xia Y et al78 have
synthesized a series of novel hydrazone derivatives of pyrazole containing
pyridines (69) and the effects of all the compounds on A549 cell growth were
investigated. The results showed that all compounds had almost inhibitory effects
on the growth of A549 cells. The study on structure activity relationships and
prediction of lipophilicities of compounds showed that compounds with Lo values
in the range of 4.12-6.80 had inhibitory effects on the growth of A549 cells.
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 76
Desai N C and Dodiya A79 have synthesized a series of 3-chloro-1-(aryl)-4-(2-(2-
chloro-6-methylquinolin-3-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)-4-ethyl-
azetidin-2-ones (70) and were screened for their antibacterial activity against four
different strains like Escherichia coli, Pseudomonas aeruginosa, Staphylococcus
aureus and Streptococcus pyogenes, while antifungal activity was determined
against three different strains like Candida albicans, Aspergillus niger and
Aspergillus clavatus. On the basis of statistical analysis, it has been observed
that compounds gave significant co-relation. Kumar R S et al80 have reported the
2,2’-{[4-(aryl)-2,6-dimethyl-1,4-dihydropyridine-3,5-diyl]dicarbonyl}dihydrazine-
carbothioamides (71) prepared from condensation between corresponding
diethylacetate and thiosemicarbazide. All the synthesized derivatives were
screened for anticoagulant properties.
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 77
Plausible mechanistic pathway of 3-(4-aryl)-1-phenyl-1H-pyrazole-4-carbaldehyde:
Plausible mechanistic pathway (sections 6-9):
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 78
Looking to the literature survey and pharmacological importance of pyrazole,
pyridine and 1,3,4-oxadiazole, we have synthesized the following hybrid
heterocyclic compounds.
Section 6: 1-(2-(3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)-5-(pyridin-4-yl)-
1,3,4-oxadiazol-3(2H)-yl)-3-(aryl)prop-2-en-1-ones.
Section 7: 1-(2-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-5-(pyridin-4-yl)-
1,3,4-oxadiazol-3(2H)-yl)-3-(aryl)prop-2-en-1-ones.
Section 8: 1-(2-(3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-5-(pyridin-4-
yl)-1,3,4-oxadiazol-3(2H)-yl)-3-(aryl)prop-2-en-1-ones.
Section 9: 1-(2-(3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)-5-(pyridin-4-yl)-
1,3,4-oxadiazol-3(2H)-yl)-3-(aryl)prop-2-en-1-ones.
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 79
EXPERIMENTAL PROCEDURE
PREPARATION OF 3-(4-ARYL)-1-PHENYL-1H-PYRAZOLE-4-CARBALDEHYDES (IIa-d) BY VILSMEIER-HAACK REACTION
Preparation of 1-(1-(4-chlorophenyl)ethylidene)-2-phenylhydrazine (Ia)
Glacial acetic acid (1mL) and phenyl hydrazine (0.01 mol) was added to a solution
of 4-chloroacetophenone (0.01 mol) in 30 mL of ethanol (95%). Then, reaction
mixture was warmed for 1 hr. The precipitates were filtered and washed with
ethanol (95%), then it was dried in vacuum over P2O5 and recrystallized from
methanol.
Preparation of 3-(4-chlorophenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde (IIa)
Dimethylformamide (0.35 mol) and phosphorus oxychloride (0.35) were
separately cooled at 0 °C before being stirred at same temperature. A solution of
compound Ia (0.11 mol) in dimethylformamide was added dropwise to the
reaction mixture which was then allowed to attain room temperature and
refluxed at 70-80 °C for 5 hrs. After cooling at room temperature, the mixture
was treated with a cold saturated K2CO3 solution. The precipitates were filtered,
strongly washed with water and recrystallized from ethanol (95%).
The progress of reaction and purity of compounds (IIa-d) were checked on TLC
[Aluminium sheet silica gel 60 F245 (E. Merck)] plates using n-hexane:ethyl
acetate (7:3) as an irrigator and plates were visualized with ultraviolet (UV) light,
or iodine vapour. All compounds were prepared by using the same method and
their physical constants are recorded in TABLE A.
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 80
PHYSICAL CONSTANTS OF OF 3-(4-ARYL)-1-PHENYL-1H-PYRAZOLE-4-CARBALDEHYDES
TABLE A
Sr.No. -R Molecular Formula
% Yield
M.P. °C
Elemental Analysis
% Carbon % Hydrogen % Nitrogen
Calcd (Found)
Calcd (Found)
Calcd (Found)
IIa -4-Cl C16H11ClN2O 72 111 67.97 (67.85)
3.92 (4.05)
9.91 (10.02)
IIb -4-F C16H11FN2O 65 183 72.17 (72.02)
4.16 (4.03)
10.52 (10.67)
IIc -4-OCH3 C17H14N2O2 68 102 73.37 (73.53)
5.07 (5.20)
10.07 (9.94)
IId -4-NO2 C16H11N3O3 58 165 65.53 (65.64)
3.78 (3.64)
14.33 (14.46)
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 81
SECTION 6
PREPARATION OF 1-(2-(3-(4-CHLOROPHENYL)-1-PHENYL-1H-PYRAZOL-4-YL)-5-(PYRIDIN-4-YL)-1,3,4-OXADIAZOL-3(2H)-YL)-3-(ARYL)PROP-2-EN-1-
ONES
SYNTHETIC SCHEME 6
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 82
PHYSICAL CONSTANTS OF 1-(2-(3-(4-CHLOROPHENYL)-1-PHENYL-1H-PYRA- ZOL-4-YL)-5-(PYRIDIN-4-YL)-1,3,4-OXADIAZOL-3(2H)-YL)-3(ARYL)PROP-2-EN-
1-ONES
TABLE 6
Sr.No. -R Molecular
Formula %
Yield M.P. °C
Elemental Analysis % Carbon % Hydrogen % Nitrogen
Calcd (Found)
Calcd (Found)
Calcd (Found)
GK6-1 -H C31H22ClN5O2 57 220 69.99 (69.90)
4.17 (4.24)
13.16 (13.24)
GK6-2 -2-Cl C31H21Cl2N5O2 61 189 65.73 (65.81)
3.74 (3.65)
12.36 (12.43)
GK6-3 -3-Cl C31H21Cl2N5O2 62 178 65.73 (65.79)
3.74 (3.66)
12.36 (12.43)
GK6-4 -4-Cl C31H21Cl2N5O2 58 212 65.73 (65.82)
3.74 (3.67)
12.36 (12.44)
GK6-5 -4-F C31H21ClFN5O2 56 180 67.70 (67.84)
3.85 (3.76)
12.73 (12.79)
GK6-6 -2-CH3 C32H24ClN5O2 59 232 70.39 (70.48)
4.43 (4.53)
12.83 (12.76)
GK6-7 -4-CH3 C32H24ClN5O2 60 241 70.39 (70.49)
4.43 (4.52)
12.83 (12.74)
GK6-8 -3-NO2 C31H21ClN6O4 64 195 64.53 (64.40)
3.67 (3.74)
14.57 (14.65)
GK6-9 -4-NO2 C31H21ClN6O4 61 218 64.53 (64.40)
3.67 (3.75)
14.57 (14.64)
GK6-10 -4-OH C31H22ClN5O3 58 201 67.94 (67.81)
4.05 (4.12)
12.78 (12.89)
GK6-11 -3-OCH3 C32H24ClN5O3 55 221 68.39 (68.50)
4.30 (4.22)
12.46 (12.55)
GK6-12 -4-OCH3 C32H24ClN5O3 59 244 68.39 (68.51)
4.30 (4.38)
12.46 (12.54)
GK6-13 -4-Br C31H21BrClN5O2 64 184 60.95 (60.80)
3.46 (3.54)
11.46 (11.56)
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 83
EXPERIMENTAL PROCEDURE
N'-((3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)isonicotino-hydrazide (IV)
Compound 3-(4-chlorophenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde IIa (0.01
mol) and isoniazide III (0.01 mol) were dissolved in 1,4-dioxane (20 mL) and the
reaction mixture were refluxed for 8 h at 90 ºC. After cooling, the crystals formed
were filtered and recrystallized from absolute alcohol to give compound IV. Yield:
78%; m.p.: 148 ºC; Anal. calcd. for C22H16ClN5O: C-65.76, H-4.01, N-17.43;
Found: C-65.63, H-4.09, N-17.53%.
1-(2-(3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)-5-(pyridin-4-yl)-1,3,4-oxa-
diazol-3(2H)-yl)ethanone (V)
Acetic anhydride (0.03 mol) was added to compound N'-((3-(4-chlorophenyl)-1-
phenyl-1H-pyrazol-4-yl)methylene)isonicotinohydrazide IV (0.01 mol) and
refluxed at 90 ºC for 5 h. After cooling, the reaction mixture was poured into ice
cold water. The precipitates were filtered, washed with water, dried and
recrystallized from ethanol (95%) to give compound V. Yield: 72%; m.p.: 168 ºC;
Anal. calcd. for C24H18ClN5O2: C-64.94, H-4.09, N-15.78; Found: C-64.81, H-
4.16, N-15.87%.
1-(2-(3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)-5-(pyridin-4-yl)-1,3,4-oxa- diazol-3(2H)-yl)-3-phenylprop-2-en-1-one (VI) (GK6-1)
A mixture of intermediate compound 1-(2-(3-(4-chlorophenyl)-1-phenyl-1H-
pyrazol-4-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)ethanone V (0.01 mol) and
benzaldehyde (0.01 mol) was stirred in ethanolic potassium hydroxide for 20 min.
at room temperature. After stirring, the reaction mixture was refluxed for 8 h and
excess of solvent was distilled out to get final compound VI. Yield: 67%; m.p.: 212
ºC; Anal. calcd. for C31H22ClN5O2: C-69.99, H-4.17, N-13.16; Found: C-69.86, H-
4.24, N-13.25%.
The progress of reaction and purity of compounds IV, V and VI were checked on
TLC [Aluminium sheet silica gel 60 F245 (E. Merck)] plates using
chloroform:methanol (9.5:0.5) as an irrigator and plates were visualized with
ultraviolet (UV) light, or iodine vapour.
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 84
SECTION 7
PREPARATION OF 1-(2-(3-(4-FLUOROPHENYL)-1-PHENYL-1H-PYRAZOL-4-YL)-5-(PYRIDIN-4-YL)-1,3,4-OXADIAZOL-3(2H)-YL)-3-(ARYL)PROP-2-EN-1-
ONES
SYNTHETIC SCHEME 7
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 85
PHYSICAL CONSTANTS OF 1-(2-(3-(4-FLUOROPHENYL)-1-PHENYL-1H-PYRA- ZOL-4-YL)-5-(PYRIDIN-4-YL)-1,3,4-OXADIAZOL-3(2H)-YL)-3-(ARYL)PROP-2-
EN-1-ONES
TABLE 7
Sr.No. -R Molecular Formula
% Yield
M.P. °C
Elemental Analysis % Carbon % Hydrogen % Nitrogen
Calcd (Found)
Calcd (Found)
Calcd (Found)
GK7-1 -H C31H22FN5O2 59 214 72.22 (72.31)
4.30 (4.37)
13.58 (13.65)
GK7-2 -2-Cl C31H21ClFN5O2 64 198 67.70 (67.82)
3.85 (3.78)
12.73 (12.81)
GK7-3 -3-Cl C31H21ClFN5O2 61 180 67.70 (67.80)
3.85 (3.77)
12.73 (12.82)
GK7-4 -4-Cl C31H21ClFN5O2 59 218 67.70 (67.79)
3.85 (3.79)
12.73 (12.80)
GK7-5 -4-F C31H21F2N5O2 56 178 69.79 (69.70)
3.97 (3.90)
13.13 (13.21)
GK7-6 -2-CH3 C32H24FN5O2 63 239 72.58 (72.47)
4.57 (4.50)
13.22 (13.29)
GK7-7 -4-CH3 C32H24FN5O2 61 257 72.58 (72.48)
4.57 (4.64)
13.22 (13.30)
GK7-8 -3-NO2 C31H21FN6O4 66 201 66.42 (66.55)
3.78 (3.69)
14.99 (14.89)
GK7-9 -4-NO2 C31H21FN6O4 62 221 66.42 (66.54)
3.78 (3.71)
14.99 (14.90)
GK7-10 -4-OH C31H22FN5O3 59 231 70.05 (70.16)
4.17 (4.25)
13.18 (13.26)
GK7-11 -3-OCH3 C32H24FN5O3 57 221 70.45 (70.34)
4.43 (4.35)
12.84 (12.94)
GK7-12 -4-OCH3 C32H24FN5O3 58 247 70.45 (70.33)
4.43 (4.50)
12.84 (12.92)
GK7-13 -4-Br C31H21BrFN5O2 67 174 62.94 (62.82)
3.56 (3.47)
11.78 (11.89)
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 86
EXPERIMENTAL PROCEDURE
N'-((3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)isonicotino-hydrazide (IV)
Compound 3-(4-fluorophenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde IIb (0.01
mol) and isoniazide III (0.01 mol) were dissolved in 1,4-dioxane (20 mL) and the
reaction mixture were refluxed for 8 h at 90 ºC. After cooling, the crystals formed
were filtered and recrystallized from absolute alcohol to give compound IV. Yield:
75%; m.p.: 153 ºC; Anal. calcd. for C22H16FN5O: C-68.56, H-4.18, N-18.17;
Found: C-68.68, H-4.09, N-18.24%.
1-(2-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-5-(pyridin-4-yl)-1,3,4-oxa-
diazol-3(2H)-yl)ethanone (V)
Acetic anhydride (0.03 mol) was added to compound N'-((3-(4-fluorophenyl)-1-
phenyl-1H-pyrazol-4-yl)methylene)isonicotinohydrazide IV (0.01 mol) and
refluxed at 90 ºC for 5 h. After cooling, the reaction mixture was poured into ice
cold water. The precipitates were filtered, washed with water, dried and
recrystallized from ethanol (95%) to give compound V. Yield: 71%; m.p.: 189 ºC;
Anal. calcd. for C24H18FN5O2: C-67.44, H-4.24, N-16.38; Found: C-67.33, H-4.16,
N-16.44%.
1-(2-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-5-(pyridin-4-yl)-1,3,4-oxa- diazol-3(2H)-yl)-3-phenylprop-2-en-1-one (VI) (GK7-1)
A mixture of intermediate compound 1-(2-(3-(4-fluorophenyl)-1-phenyl-1H-
pyrazol-4-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)ethanone V (0.01 mol) and
benzaldehyde (0.01 mol) was stirred in ethanolic potassium hydroxide for 20 min.
at room temperature. After stirring, the reaction mixture was refluxed for 8 h and
excess of solvent was distilled out to get final compound VI. Yield: 59%; m.p.: 214
ºC; Anal. calcd. for C31H22FN5O2: C-72.22, H-4.30, N-13.58; Found: C-72.31, H-
4.37, N-13.65%.
The progress of reaction and purity of compounds IV, V and VI were checked on
TLC [Aluminium sheet silica gel 60 F245 (E. Merck)] plates using
chloroform:methanol (9.5:0.5) as an irrigator and plates were visualized with
ultraviolet (UV) light, or iodine vapour.
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 87
SECTION 8
PREPARATION OF 1-(2-(3-(4-METHOXYPHENYL)-1-PHENYL-1H-PYRAZOL-4-YL)-5-(PYRIDIN-4-YL)-1,3,4-OXADIAZOL-3(2H)-YL)-3-(ARYL)PROP-2-EN-1-
ONES
SYNTHETIC SCHEME 8
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 88
PHYSICAL CONSTANTS OF 1-(2-(3-(4-METHOXYPHENYL)-1-PHENYL-1H-PYRAZOL-4-YL)-5-(PYRIDIN-4-YL)-1,3,4-OXADIAZOL-3(2H)-YL)-3-
(ARYL)PROP-2-EN-1-ONES
TABLE 8
Sr.No. -R Molecular Formula
% Yield
M.P. °C
Elemental Analysis % Carbon % Hydrogen % Nitrogen
Calcd (Found)
Calcd (Found)
Calcd (Found)
GK8-1 -H C32H25N5O3 61 221 72.85 (72.73)
4.78 (4.86)
13.27 (13.36)
GK8-2 -2-Cl C32H24ClN5O3 65 213 68.39 (68.28)
4.30 (4.38)
12.46 (12.54)
GK8-3 -3-Cl C32H24ClN5O3 63 227 68.39 (68.48)
4.30 (4.23)
12.46 (12.53)
GK8-4 -4-Cl C32H24ClN5O3 64 237 68.39 (68.49)
4.30 (4.37)
12.46 (12.37)
GK8-5 -4-F C32H24FN5O3 59 198 70.45 (70.34)
4.43 (4.50)
12.84 (12.92)
GK8-6 -2-CH3 C33H27N5O3 64 231 73.18 (73.28)
5.02 (5.10)
12.93 (12.85)
GK8-7 -4-CH3 C33H27N5O3 61 247 73.18 (73.29)
5.02 (5.09)
12.93 (12.84)
GK8-8 -3-NO2 C32H24N6O5 66 207 67.13 (67.04)
4.22 (4.30)
14.68 (14.76)
GK8-9 -4-NO2 C32H24N6O5 64 234 67.13 (67.05)
4.22 (4.29)
14.68 (14.77)
GK8-10 -4-OH C32H25N5O4 66 249 70.71 (70.82)
4.64 (4.71)
12.88 (12.79)
GK8-11 -3-OCH3 C33H27N5O4 61 224 71.08 (71.19)
4.88 (4.95)
12.56 (12.48)
GK8-12 -4-OCH3 C33H27N5O4 63 251 71.08 (71.00)
4.88 (4.95)
12.56 (12.47)
GK8-13 -4-Br C32H24BrN5O3 67 203 63.37 (63.26)
3.99 (3.92)
11.55 (11.64)
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 89
EXPERIMENTAL PROCEDURE
N'-((3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)isonicotino-hydrazide (IV)
Compound 3-(4-methoxyphenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde IIc (0.01
mol) and isoniazide III (0.01 mol) were dissolved in 1,4-dioxane (20 mL) and the
reaction mixture were refluxed for 8 h at 90 ºC. After cooling, the crystals formed
were filtered and recrystallized from absolute alcohol to give compound IV. Yield:
79%; m.p.: 173 ºC; Anal. calcd. for C23H19N5O2: C-69.51, H-4.82, N-17.62; Found:
C-69.40, H-4.89, N-17.70%.
1-(2-(3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-5-(pyridin-4-yl)-1,3,4-
oxadiazol-3(2H)-yl)ethanone (V)
Acetic anhydride (0.03 mol) was added to compound N'-((3-(4-methoxyphenyl)-1-
phenyl-1H-pyrazol-4-yl)methylene)isonicotinohydrazide IV (0.01 mol) and
refluxed at 90 ºC for 5 h. After cooling, the reaction mixture was poured into ice
cold water. The precipitates were filtered, washed with water, dried and
recrystallized from ethanol (95%) to give compound V. Yield: 72; m.p.: 189 ºC;
Anal. calcd. for C25H21N5O3: C-68.33, H-4.82, N-15.94; Found: C-68.45, H-4.74,
N-15.85%.
1-(2-(3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)-3-phenylprop-2-en-1-one (VI) (GK8-1)
A mixture of intermediate compound 1-(2-(3-(4-methoxyphenyl)-1-phenyl-1H-
pyrazol-4-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)ethanone V (0.01 mol) and
benzaldehyde (0.01 mol) was stirred in ethanolic potassium hydroxide for 20 min.
at room temperature. After stirring, the reaction mixture was refluxed for 8 h and
excess of solvent was distilled out to get final compound VI. Yield: 61%; m.p.: 221
ºC; Anal. calcd. for C32H25N5O3: C-72.85, H-4.78, N-13.27; Found: C-72.73, H-
4.86, N-13.36%.
The progress of reaction and purity of compounds IV, V and VI were checked on
TLC [Aluminium sheet silica gel 60 F245 (E. Merck)] plates using
chloroform:methanol (9.5:0.5) as an irrigator and plates were visualized with
ultraviolet (UV) light, or iodine vapour.
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 90
SECTION 9
PREPARATION OF 1-(2-(3-(4-NITROPHENYL)-1-PHENYL-1H-PYRAZOL-4-YL)-5-(PYRIDIN-4-YL)-1,3,4-OXADIAZOL-3(2H)-YL)-3-(ARYL)PROP-2-EN-1-ONES
SYNTHETIC SCHEME 9
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 91
PHYSICAL CONSTANTS OF 1-(2-(3-(4-NITROPHENYL)-1-PHENYL-1H-PYRA- ZOL-4-YL)-5-(PYRIDIN-4-YL)-1,3,4-OXADIAZOL-3(2H)-YL)-3-(ARYL)PROP-2-
EN-1-ONES
TABLE 9
Sr.No. -R Molecular Formula
% Yield
M.P. °C
Elemental Analysis % Carbon % Hydrogen % Nitrogen
Calcd (Found)
Calcd (Found)
Calcd (Found)
GK9-1 -H C31H22N6O4 62 199 68.63 (68.52)
4.09 (4.02)
15.49 (15.58)
GK9-2 -2-Cl C31H21ClN6O4 63 211 64.53 (64.66)
3.67 (3.57)
14.57 (14.68)
GK9-3 -3-Cl C31H21ClN6O4 65 224 64.53 (64.65)
3.67 (3.75)
14.57 (14.66)
GK9-4 -4-Cl C31H21ClN6O4 61 241 64.53 (64.67)
3.67 (3.58)
14.57 (14.67)
GK9-5 -4-F C31H21FN6O4 60 197 66.42 (66.54)
3.78 (3.69)
14.99 (14.90)
GK9-6 -2-CH3 C32H24N6O4 59 229 69.06 (69.19)
4.35 (4.26)
15.10 (15.19)
GK9-7 -4-CH3 C32H24N6O4 64 257 69.06 (69.18)
4.35 (4.27)
15.10 (15.18)
GK9-8 -3-NO2 C31H21N7O6 67 238 63.37 (63.24)
3.60 (3.68)
16.69 (16.79)
GK9-9 -4-NO2 C31H21N7O6 68 214 63.37 (63.24)
3.60 (3.66)
16.69 (16.77)
GK9-10 -4-OH C31H22N6O5 65 261 66.66 (66.78)
3.97 (3.90)
15.05 (14.98)
GK9-11 -3-OCH3 C32H24N6O5 62 234 67.13 (67.01)
4.22 (4.30)
14.68 (14.78)
GK9-12 -4-OCH3 C32H24N6O5 63 263 67.13 (67.03)
4.22 (4.31)
14.68 (14.79)
GK9-13 -4-Br C31H21BrN6O4 69 189 59.91 (59.80)
3.41 (3.48)
13.52 (13.60)
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 92
EXPERIMENTAL PROCEDURE
N'-((3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)isonicotino-hydrazide (IV)
Compound 3-(4-nitrophenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde IId (0.01 mol)
and isoniazide III (0.01 mol) were dissolved in 1,4-dioxane (20 mL) and the
reaction mixture were refluxed for 8 h at 90 ºC. After cooling, the crystals formed
were filtered and recrystallized from absolute alcohol to give compound IV. Yield:
77%; m.p.: 178 ºC; Anal. calcd. for C22H16N6O3: C-64.07, H-3.91, N-20.38; Found:
C-64.19, H-3.84, N-20.29%.
1-(2-(3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)-5-(pyridin-4-yl)-1,3,4-oxadi-
azol-3(2H)-yl)ethanone (V)
Acetic anhydride (0.03 mol) was added to compound N'-((3-(4-nitrophenyl)-1-
phenyl-1H-pyrazol-4-yl)methylene)isonicotinohydrazide IV (0.01 mol) and
refluxed at 90 ºC for 5 h. After cooling, the reaction mixture was poured into ice
cold water. The precipitates were filtered, washed with water, dried and
recrystallized from ethanol (95%) to give compound V. Yield: 70; m.p.: 177 ºC;
Anal. calcd. for C24H18N6O4: C-63.43, H-3.99, N-18.49; Found: C-63.31, H-4.07,
N-18.58%.
1-(2-(3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)-5-(pyridin-4-yl)-1,3,4-oxadi- azol-3(2H)-yl)-3-phenylprop-2-en-1-one (VI) (GK9-1)
A mixture of intermediate compound 1-(2-(3-(4-nitrophenyl)-1-phenyl-1H-
pyrazol-4-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)ethanone V (0.01 mol) and
benzaldehyde (0.01 mol) was stirred in ethanolic potassium hydroxide for 20 min.
at room temperature. After stirring, the reaction mixture was refluxed for 8 h and
excess of solvent was distilled out to get final compound VI. Yield: 62%; m.p.: 199
ºC; Anal. calcd. for C31H22N6O4: C-68.63, H-4.09, N-15.49; Found: C-68.52, H-
4.02, N-15.58%.
The progress of reaction and purity of compounds IV, V and VI were checked on
TLC [Aluminium sheet silica gel 60 F245 (E. Merck)] plates using
chloroform:methanol (9.5:0.5) as an irrigator and plates were visualized with
ultraviolet (UV) light, or iodine vapour.
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 93
References
1. Elguero J; “in comprehensive Heterocyclic Chemistry II: Pyrazoles eds,
Katritzky AR, Rees CW, Scriven EFV, Ed., Pergamon Press, Oxford, 3, 1-
75, 1996.
2. Lyga JW, Patera RM, Plummer MJ, Halling BP, Yuhas DA; Pestic Sci, 42,
29, 1994.
3. Simoni D, Roberti M, Paolo IF, Rondanin R, Baruchello R, Malagutti C,
Mazzali A, Rossi M, Grimaudo S, Capone F, Dusonchet L, Meli M,
Raimondi MV, Landino M, D’Alessandro N, Tolomeo M, Arindam D, Lu S,
Benbrook DM; J Med Chem, 44, 2308, 2001.
4. Demers J, Hageman W, Johnson S, Klaubert D, Look R, Moore J; Bioorg
Med Chem Lett, 4, 2451, 1994.
5. Shin KD, Lee MY, Shin DS, Lee S, Son KH, Koh S, Paik YK, Kwon BM, Han
DC; J Biol Chem, 280, 41439, 2005.
6. Liu XH, Cui P, Song BA, Bhadury PS, Zhu HL, Wang SF; Bioorg Med Chem,
16, 4075, 2008.
7. Magedov IV, Manpadi M, Van slambrouck S, Steelant WFA, Rozhkova E,
Przheval’skii NM, Rogelj S, Kornienko A; J Med Chem, 50, 5183, 2007.
8. Velaparthi S, Brunsteiner M, Uddin R, Wan B, Franzblau SG, Petukhov
PA; J Med Chem, 51, 1999, 2008.
9. Rowley M, Broughton HB, Collins I, Baker R, Emms F, Marwood R, Patel
S, Ragan CI, Freedman SB, Leeson PD; J Med Chem, 39, 1943, 1996.
10. Wittenberger SJ; J Org Chem, 61, 356, 1996.
11. Dannhardt G, Laufer S; Curr Med Chem, 7, 1101, 2000.
12. Ashton WT, Hutchines SM, Greenlee WJ, Doss GA, Chang RSL, Lotti VJ,
Faust KA, Chen TB; J Med Chem, 36, 3595, 1993.
13. Genin MJ, Biles C, Keiser BJ, Poppe SM, Swaney SM, Tarpley WG, Yagi Y,
Romero DL; J Med Chem, 43, 1034, 2000.
14. Penning PD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S,
Graneto MJ, Lee LF, Isakson PC; J Med Chem, 40, 1347, 1997.
15. Habeeb AG, Rao PNP, Knaus EE; J Med Chem, 44, 3039, 2001.
16. Fink BE, Mortensen DS, Stauffer SR, Aron, ZD, Katzenellenbogen JA;
Chem Biol, 6, 205, 1999.
17. Stauffer SR, Katzenellenbogen JA; J Comb Chem, 2, 318, 2000.
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 94
18. Astead GM, Carlson KE, Katzenellenbogen JA; Steroids, 62, 268, 1997.
19. Stauffer SR, Huang Y, Coletta CJ, Tedesco R, Katzenellebogen JA; Bioorg
Med Chem, 9, 141, 2001.
20. Bonacorso HG, Wentz AP, Lourega RV, Cechinel CA, Moraes TS, Coelho
HS, Zanatta N, Martins AP, Hoerner, M, Alves SH; J Fluorine Chem, 127,
1066, 2006.
21. Rich S, Horsfall JG; Phytopathology, 42, 457, 1952.
22. Sakya SM, Rast B; Tetrahedron Lett, 44, 7629, 2003.
23. Grotjahn DB, Van S, Combs D, Lev DA, Schneider C, Rideout M, Meyer C,
Hernandez G, Mejorado L; J Org Soc, 67, 9200, 2002.
24. Alberola A, Calvo L, Ortega AG, Adaba ML, Sanudo MC, Granda SG,
Rodriguez EG; Heterocycles, 51, 2675, 1999.
25. Almirante N, Cerri A, Fedrizzi G, Marazzi G, Santagostino M; Tetrahedron
Lett, 39, 3287, 1998.
26. Luo Y, Potvin PG; J Org Chem, 59, 1761, 1994.
27. Braibante MEF, Clar G, Martin MAP; J Heterocycl Chem, 30, 1159, 1993.
28. Bohrisch J, Patzel M, Mugge C, Liebscher J; Synthesis, 1153, 1991.
29. Lyga JW, Patera RM; J Heterocycl Chem, 30, 919, 1990.
30. Kashira C, Harada H, Kita I, Fukuchi I, Hosomi A; Synthesis, 61, 1994.
31. Mikulskiene G, Mickevicius V, Brokaite K; ARKIVOC, 2, 1, 2006.
32. Giacomelli G, Porcheddu A, Salaris M, Taddei M; Eur J Org Chem, 3, 537,
2003.
33. Lee KY, Kim JM, Kim JN; Tetrahedron Lett, 44, 6737, 2003.
34. Alinezhad H, Tajbakhsh M, Zare M; J Mex Chem Soc, 55(4), 238, 2011.
35. Sharma PK, Kumar S, Kumar P, Kaushik P, Kaushik D, Dhingra Y, Aneja
KR; Eur J Med Chem, 45, 2650, 2010.
36. Mohamed S, Ahmed M, Kobayashi K, Mori A; Org Lett, 7, 4487, 2005.
37. Fadda AA, Abdel-Latif E, El-Mekawy RE; Eur J Med Chem, 44, 1250, 2009.
38. Ming L, Li-Rong, W, Wei-Jun F, Gui-Long Z, Fang-Zhong H, Hua-Zheng Y,;
Chin J Chem, 22, 1064, 2004.
39. Farag AM, Ali KAK, El-Debss TMA, Mayhoub AS, Amr E, Abdel-Hafez NA,
Abdulla MM; Eur J Med Chem, 45, 5887, 2010.
40. Chovatia PT, Akabari JD, Kachhadia PK, Zalavadia PD, Joshi HS; J Serb
Chem Soc, 71, 713, 2007.
41. Badawey ESAM, El-Hawash SAM; Eur J Med Chem, 41, 155, 2006.
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 95
42. Banoglu E, Sukuroglu M, Ergun BC, Baytas SN, Aypar E, Ark M; Turk J
Chem, 31, 677, 2007.
43. Karthikeyan MS, Holla BS, Kumari NS; Eur J Med Chem, 42, 30, 2007.
44. Yadlapalli RK, Chourasia OP, Vemuri K, Sritharan M, Perali RS; Bioorg
Med Chem Lett, 22, 2708, 2012.
45. Farhanullah F, Agarwal N, Goel A, Ram VJ; J Org Chem, 68, 2983, 2003.
46. Joule JA, Smith G, Mills K; Heterocyclic chemistry; 3rd ed. Chapman and
Hall: London, 72, 1995.
47. Matolcsy G; Pesticide Chemistry; Elsevier Scientific: Amsterdam, Oxford,
427, 1988.
48. Scriven E, Berry D; Speciality Chem Mag, 24, 2001.
49. Kozhevnikov VN, Kozhevnikov DN, Nikitina TV, Rusinov VL, Chupakhin
OL, Zabel M, Konig B; J Org Chem, 68, 2882, 2003.
50. Joshi HS, Kachhadia VV, Patel MR; J Sci I R Iran, 15(1), 47, 2004.
51. Xiong X, Bagley MC, Chapaneri K; Tetrahedron Lett, 45, 6121, 2004.
52. Andersson H, Almqvist F, Olsson R; Org Lett, 9, 1335, 2007.
53. Trost BM, Gutierrez AC, Org Lett, 9, 1473, 2007.
54. Fathalla OEM, Kassem EMM, Ibrahem NM, Kamel MM; Acta poloniac
pharmaceutica–Drug research, 65(1), 11, 2008.
55. Thirumurugan P, Perumal PT; Tetrahedron, 65, 7620, 2009.
56. Barluenga J, Jimenez-Aquino A, Fernandez MA, Aznar F, Valdes C;
Tetrahedron, 64, 778, 2008.
57. Palacios F, Herran E, Rubiales G, Alonso C; Tetrahedron, 63, 5669, 2007.
58. Teague SJ; J Org Chem, 73, 9765, 2008.
59. Movassaghi M, Hill MD, Ahmad OK; J Am Chem Soc, 129, 10096, 2007.
60. Arora VK, Knaus EE; J Heterocycl Chem, 36, 201, 1999.
61. Cesur N, Cesur Z; Farmaco, 49, 679, 1994.
62. Mosti L, Menozzi G, Schenone P, Dorigo P, Gaion RM, Belluco P; Il
Farmaco, 47, 427, 1992.
63. Hojo M, Tanaka Y, Katayama O, Teramoto N; Arzneim Forsch, 43, 847,
1993.
64. Manna F, Bolasco A, Bizzari B, Lena R, Chimenti F; Il Farmaco, 51, 579,
1996.
65. a) Triggle DJ; Mini-Rev Med Chem, 3, 215, 2003; b) Budriesi R, Bisi A, Ioan
P, Rampa A, Gobbi S, Belluti F, Piazzi L, Valenti P, Chiarini A; Bioorg Med
Studies on clinically important nitrogen and sulphur containing heterocyclic compounds
DECEMBER 2013 Page 96
Chem, 13, 3423, 2005. c) Velazquez C, Knaus EE; Bioorg Med Chem, 12,
3831, 2004.
66. Mak IT, Zhang J, Weglicki WB; Pharmacol Res, 45, 27, 2002.
67. a) Jain P, Narang G, Jindal DP, Bansal R, Calle C, Carron R, Pemberton K,
Harvey AL; Pharmazie, 61, 400, 2006; b) Visentin S, Rolando B, Di Stilo A,
Fruttero R, Novara M, Carbone E, Roussel C, Vanthuyne N, Gasco A; J
Med Chem, 47, 2688, 2004.
68. a) Hilgeroth A; Mini-Rev Med Chem, 2, 235, 2002; b) Hilgeroth A, Billich A,
Lilie H; Eur J Med Chem, 36, 367, 2001; c) Hilgeroth A, Dressler C,
Neuhoff S, Spahn-Langguth H, Langguth P; Pharmazie, 55, 784, 2000. d)
Hilgeroth A, Langner A; Pharmazie, 55, 542, 2000.
69. Bringmann G, Reichert Y, Kane VV; Tetrahedron, 60, 3539, 2004.
70. Zhou Y, Kijima T, Kuwahara S, Watanabe M, Izumi T; Tetrahedron Lett,
49, 3757, 2008.
71. a) Cooke MW, Hanan GS; Chem Soc Rev, 36, 1466, 2007; b) Constable EC;
Chem Soc Rev, 36, 246, 2007; c) Kurth DG, Higuchi M; Soft Matter, 2, 915,
2006; d) Medlycott EA, Hanan GS; Chem Soc Rev, 34, 133, 2005; e)
Andres, PR, Schubert US; Adv Mater, 16, 1043, 2004.
72. Narendar P, Parthiban J, Anbalagan N, Gunasekaran V, Leonard JT; Biol
Pharm Bull, 26, 182, 2003.
73. Bach P, Bostrom J, Brickmann K, Van Giezen JJJ, Groneberg RD, Harvey
DM, O’Sullivan M, Zetterberg F; Eur J Med Chem, 65, 360, 2013.
74. Hayashi S, Ueno N, Murase A, Nakagawa Y, Takada J; Eur J Med Chem,
50, 179, 2012.
75. Prasanthi G, Prasad KVSRG, Bharathi K; Eur J Med Chem, 66, 516, 2013.
76. Khidre RE, Abu-Hashem AA, El-Shazly M; Eur J Med Chem, 46, 5057,
2011.
77. Acharya BN, Saraswat D, Tiwari M, Shrivastava AK, Ghorpade R, Bapna S,
Kaushik MP; Eur J Med Chem, 45, 430, 2010.
78. Xia Y, Fan CD, Zhao BX, Zhao J, Shin DS, Miao JY; Eur J Med Chem, 43,
2347, 2008.
79. Desai NC, Dodiya AM; J Saudi Chem Soc, doi:10.1016/j.jscs.2011.09.005.
80. Kumar RS, Idhayadhulla A, Nasser AJA, Selvin J; Eur J Med Chem, 46,
804, 2011.
top related